C5 and Sepsis: Additionally, clinical trials were conducted for efficacy analysis of anti-C5a monoclonal antibody (CaCP29, InflaRx GmbH) (NCT02246595) and of an MD2-TLR4 antagonist (Eritoran, Eisai) in severe sepsis (NCT00334828), but without any clinical effect.